Your session is about to expire
← Back to Search
Neuromodulation
Transcranial direct current stimulation for Young Adults
N/A
Recruiting
Research Sponsored by Butler Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Must not have
Currently prescribed psychiatric medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
Summary
This trial is testing whether they can change brain networks related to response inhibition in healthy young adults, which may help improve treatments for disorders that have difficulties with inhibitory control.
Who is the study for?
This trial is for healthy young adults who either have very good or poor inhibitory control, as measured by the BRIEF-Inhibit scale. Participants must speak English fluently. Those with active mania, psychosis, substance abuse disorders, psychiatric medications, inability to undergo MRI, certain medical conditions like epilepsy or brain injuries, and women not using contraception are excluded.Check my eligibility
What is being tested?
The study investigates how transcranial direct current stimulation (tDCS) affects brain networks and behavior related to response inhibition in healthy young adults. It aims to understand the brain's role in inhibitory control which could improve treatments for disorders where such control is compromised.See study design
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site on the scalp, itching or tingling during stimulation, headache after treatment sessions, fatigue or nausea. Serious side effects are rare but can include seizures if pre-existing conditions are present.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently taking medication for a mental health condition.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
fMRI connectivity at rest
fMRI connectivity during a stop signal task
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Impulsive Participants- Active StimulationExperimental Treatment1 Intervention
Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to active stimulation.
Group II: Cautious ParticipantsActive Control1 Intervention
Participants who have low scores on a self-report of inhibitory control abilities (BRIEF-Inhibit).
Group III: Impulsive Participants- Sham StimulationPlacebo Group1 Intervention
Participants who have high scores on a self-report of inhibitory control abilities (BRIEF-Inhibit) who are randomized to sham stimulation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial direct current stimulation
2012
Completed Phase 3
~650
Find a Location
Who is running the clinical trial?
Butler HospitalLead Sponsor
130 Previous Clinical Trials
16,385 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I don't have conditions like epilepsy, brain injury, or a brain tumor, and I'm not pregnant without contraception.I am currently taking medication for a mental health condition.You are currently experiencing extreme mood swings or hallucinations.You currently have a problem with drugs or alcohol.
Research Study Groups:
This trial has the following groups:- Group 1: Cautious Participants
- Group 2: Impulsive Participants- Active Stimulation
- Group 3: Impulsive Participants- Sham Stimulation
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger